Aerosol drug inhibition of lung metastases

Details Aerosol drug inhibition of lung metastases Aerosol drug inhibition of lung metastases

2007-10-30

2007-10-30

Canella, Karen A. (Department: 1643)

Drug, bio-affecting and body treating compositions

Radionuclide or intended radionuclide containing; adjuvant...

In aerosol, fine spray, effervescent, pressurized fluid,...

C424S001210, C424S450000

Reexamination Certificate

active

10439773

ABSTRACT:
The present invention provides a method of inhibiting growth of lung metastases in an individual comprising the steps of administering a dose of a lipid-drug enhancer liposomal complex and, in sequence, administering a dose of a lipid-anticancer drug liposomal complex. Furthermore, the lipid-drug enhancer liposomal complex may be administered in a continuing dose with the lipid-anticancer drug liposomal complex whereby both liposomal complexes are mixed in the nebulizer. Methods of inhibiting growth of lung metastases in an individual by the sequential administration via aerosolization of a dilauroylphosphatidylcholine-cyclosporin A liposomal complex and a dilauroylphosphatidylcholine-paclitaxel liposomal complex are also provided.

REFERENCES:
patent: 6090407 (2000-07-01), Knight et al.
patent: 6090955 (2000-07-01), Reszka et al.
patent: WO 98/00111 (1998-01-01), None
Waldrep et al (International Journal of Pharmaceutics, 1993, vol. 97, pp. 205-212.
Ross et al (Clinical Cancer Research, 1997, vol. 3, pp. 57-62).
The abstract of Ross et al (Proceed Amer Assoc Cancer Res, Mar. 1999, vol. 40, p. 187).
The abstract of Koshkina et al (Proceed Amer Assoc Cancer Res, Mar. 2001, vol. 42, p. 374).
Cabanes et al., “Comparative in vivo studies with paclitaxel and liposome-encapsulated paclitaxel,”Int. J. Oncol., 12:1035-1040, 1998.
Choy et al., “The current state of paclitaxel and radiation in the combined-modality therapy of non-small cell lung cancer,”Semin. Oncol., 28(Suppl 14):17-22, 2001.
Cresteil et al., “Taxol metabolism by human liver microsomes: identification of cytochrome P450 isozymes involved in its biotransformation,”Cancer Res., 54:386-392, 1994.
Fujitaka et al., “Induction of cytochrome P450 3A4 by docetaxel in peripheral mononuclear cells and its expression in lung cancer,”Cancer Chemother. Pharmacol., 48:42-46, 2001.
Germann, “Detection of recombinant P-glycoprotein in multidrug resistant cultured cells,”Mol. Biotechnol., 14:131-145, 2000.
Gilbert et al., “Characterization and administration of cyclosporine liposomes as a small-particle aerosol,”Transplantation, 56:974-977, 1993.
Gilbert et al., “Cyclosporin a Liposome Aerosol: Lack of Acute Toxicity in Rats with a High Incidence of Underlying Pneumonitis,”Inhalation Taxicology, 9:717-730, 1997.
Gilbert et al., “Tolerance of volunteers to cyclosporine A—dilauroylphosphatidylcholine liposome aerosol,”Am. J. Respir. Crit. Care Med., 156:1789-1793, 1997.
Gottesman et al., “Biochemistry of multidrug resistance mediated by the multidrug transporter,”Annu. Rev. Biochem., 62:385-427, 1993.
Knight et al., “Anti-cancer activity of 9-nitrocaptothecin liposome aerosol in mice,”Transactions of the American Clinical and Climatological Association, 111:135-145, 2000.
Knight et al., “Anticancer effect of 9-nitrocamptothecin liposome aerosol an human cancer xenografts in nude mice,”Cancer Chemother. Pharmacol., 44:177-86, 1999.
Koshkina et al., “9-Nitrocamptothecin liposome aerosol treatment of melanoma and osteosarcoma lung metastases in mice,”Clinical Cancer Research, 6:2876-2880, 2000.
Koshkina et al., “Improved respiratory delivery of the anticancer drugs, camptothecin and paclitaxel with 5% CO2-enriched air: pharmacokinetic studies,”Cancer Chemother. Pharmacol., 47:451-456, 2001.
Koshkina et al., “Paclitaxel liposome aerosol treatment induces inhibition of pulmonary metastases in murine renal carcinoma model,”Clinical Cancer Research, 7:3258-3262, 2001.
Kosmas et al., “Gemcitabine and docetaxel as second-line chemotherapy for patients with nonsmall cell lung carcinoma who fail prior paclitaxel plus platinum-based regimens,”Cancer, 92:2902-2910, 2001.
Meerum-Terwogt et al., “Coadministration of oral cyclosporin A enables oral therapy with paclitaxel,”Clin. Cancer Res., 5:3379-3384, 1999.
Remuzzi and Perico, Cyclosporine-induced renal dysfunction in experimental animals and humans,Kidney Int. Suppl., 52:S70-74, 1995.
Ross et al., “Cyclosporin A enhances paclitaxel toxicity against leukemia and respiratory epithelial cancers,”Clin. Cancer, Res., 3:57-62, 1997.
Rowinsky and Donehower, “Paclitaxel (taxol),”N. Engl. J. Med., 332:1004-1014, 1995.
Sakai et al., “A phse II studyof paclitaxel plus cisplatin for advanced non-small-cell lung cancer in Japanese patients,”Cancer Chemother. Pharmacol., 48:499-503, 2001.
Schiff and Horwitz, “Taxol stabilizes microtubules in mouse fibroblast cells,”Proc. Natl. Acad. Sci. USA, 77:1561-1565, 1980.
Sharma et al., “Activity of paclitaxel liposome formulations against human ovarian tumor xenografts,”Int. J. Cancer, 71:103-107, 1997.
Sikic et al., “Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein,”Cancer Chemother. Pharmacol., 40(Suppl):S13-19, 1997.
Sonnichsen et al., “Variability in human cytochrome P450 paclitaxel metabolism,”J. Pharmacol. Exp. Ther., 275:566-575, 1995.
Sood et al., “Cyclosporin A reverses chemoresistance in patients with gynecologic malignancies,”Neoplasia. 1:118-222, 1999.
Sugawara et al., “Lung resistance protein (LRP) expression in human normal tissues in comparison with that of MDR1 and MRP,”Cancer Lett., 112:23-31, 1997.
Verschraegen et al., “Clinical Evaluation of the Delivery and Safety of Aerosolized Liposomal 9-Nitro-20(S)-Camptothecin in Patients with Advanced Pulmonary Malignancies,”Clin. Cancer Res., 10:2319-2326, 2004.
Wandel et al., “P-glycoprotein and cytochrome P-450 3A inhibition: dissociation of inhibitory potencies,”Cancer Res., 59:3944-3948, 1999.
Weiss et al., “Hypersensitivity reactions from taxol,”J. Clin. Oncol., 8:1263-1268, 1990.
Yokoyama et al., “Immunohistochemical evidence that P-glycoprotein in non-small cell lung cancers is associated with shorter survival,”Surg. Today, 29:1141-7, 1999.
Younes et al., “Local tumor irradiation augments the response to IL-2 therapy in a murine renal adenocarcinoma,”Cell Immunol., 165:243-251, 1995.

Affiliated with

Also associated with

Rating

Aerosol drug inhibition of lung metastases does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Aerosol drug inhibition of lung metastases, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Aerosol drug inhibition of lung metastases will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3838134